ASTH Astrana Health, Inc.
Services-Management Consulting Services · Nasdaq · SEC CIK 1083446 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY35.1%
TTM net income YoY457.1%
TTM EPS YoY468.4%
Revenue 3-yr CAGR43.4%
Net income 3-yr CAGR6.0%
Margins
Gross margin11.0%
Operating margin3.1%
Net margin1.4%
FCF margin2.5%
EBITDA margin4.7%
Returns
ROE6.5%
ROA2.3%
ROIC (approx.)5.9%
Asset turnover1.71x
Leverage & solvency
Liabilities / assets73.1%
Debt / equity1.08x
Current ratio1.25x
Interest coverage1.87x
Cash quality & payout
Operating cash flow / net income2.15x
Accruals ratio-2.7%
Payout ratio5.1%
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.18B | $2.03B |
| Cost of revenue | $2.84B | $1.76B |
| Gross profit | $341.53M | $271.39M |
| SG&A expense | $217.26M | $154.11M |
| Operating income | $78.53M | $89.35M |
| Interest expense | $49.93M | $33.10M |
| Pretax income | $39.61M | $80.82M |
| Income tax | $15.53M | $30.89M |
| Net income | $22.49M | $43.15M |
| EBITDA | $124.27M | $117.28M |
| EPS (basic) | 0.46 | 0.91 |
| EPS (diluted) | 0.46 | 0.90 |
| Weighted avg. shares (diluted) | 49.37M | 47.97M |
| Balance sheet | ||
| Cash & equivalents | $429.47M | $289.10M |
| Short-term investments | — | $2.38M |
| Receivables | $374.46M | $275.99M |
| Current assets | $863.31M | $638.50M |
| PP&E, net | $57.33M | $14.27M |
| Goodwill | $865.30M | $419.25M |
| Intangibles | $270.97M | $118.18M |
| Total assets | $2.22B | $1.35B |
| Current liabilities | $615.27M | $365.61M |
| Short-term debt | $47.87M | $9.38M |
| Long-term debt | $990.90M | $425.30M |
| Total debt | $1.04B | $434.67M |
| Total liabilities | $1.66B | $840.73M |
| Shareholders' equity | $779.29M | $712.72M |
| Net debt | $609.29M | $145.57M |
| Shares outstanding | 48.89M | 47.93M |
| Cash flow statement | ||
| Operating cash flow | $114.60M | $52.20M |
| Capital expenditure | $10.11M | $8.03M |
| Free cash flow | $104.49M | $44.17M |
| Investing cash flow | -$539.00M | -$192.40M |
| Financing cash flow | $569.35M | $135.15M |
| Depreciation & amortization | $45.75M | $27.93M |
| Stock-based compensation | $38.60M | $34.54M |
| Dividends paid | $7.88M | $4.04M |
| Share buybacks | $25.60M | $900,000 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.